Experimental data on IMMUNOFAN
1.Pharmacological properties.
1.1. IMMUNOFAN has a powerful immunoregulating activity in
respect of restoration of disturbed indicators of the cellular and
humeral immunity.
1.2. The drug stimulates the processes of the T-lymphocytes
maturing and cooperative interaction of T-helpers and bone marrow
cells, restores the disturbed balance of T-lymphocytes subpopulations,
intensifies the activity of the natural killers and the oxygen
depended system bacterial action of the neutrophils.
1.3. On the background of congenital or acquired immunopathology
IMMUNOFAN activates earlier stages of antibody production, increases
synthesis of immunoglobulins M, G, A, but in the case of the Ig E
hyper production it decreases its synthesis level.
1.4. IMMUNOFAN stimulates disturbed production of the thymic
immunity hormones, including serum thymic factor and increases the
amount of antibody producing cells in 4-6 times.
1.5. IMMUNOFAN regulates formation of immune system mediators
depending on their production level. In conditions of decreasing
lymphocytes proliferating activity the drug stimulates expression of
receptors and formation of interleukine-2 (drug induced or ecological
immunodeficiency). On the background of induced hyperproduction of
tumor necrosis factor the drug decreases its activity.
1.6. The drug increases the antibacterial and antiviral resistance
of the host, its administration existentially increases the survival
of experimental animals after Klebsiella pneumoniae infection and
viability of the posterity after influenza virus infection.
1.7. IMMUNOFAN administration in the case of immunization by
antiviral vaccine increases titters and the duration of the antiviral
antibodies circulation sharply.
1.8. In the case of the chronic infectious process decompensation
the drug normalize the lymphocytes genetic stability according the
DNA structure stabilizing indicator and its ability of reparation.
1.9. IMMUNOFAN's pharmacological effect does not depend on the
prostaglandin E^2 production level and is reached in combination with
anti-inflammatory drugs of the non steroid group (prostaglandins
inhibitors).
1.10. IMMUNOFAN has an exceptional low toxicity and provides the
wide safety reserve. The single dose as higher as 1000 middle
therapeutic dose does not cause deaths in the experimental animals.
1.11. Determination of the drug chronic toxicity demonstrates its
safety. Changes of the hematological and biochemical indicators
occurred during the IMMUNOFAN administration to the animals daily
during one month in therapeutic or subtoxic dose come back to the
initial levels after withdrawal of IMMUNOFAN.
1.12. The IMMUNOFAN administration does not cause local irritating
effect, allergic reactions and mutagenesis.
1.13. The close analog of IMMUNOFAN is Thymopentin (Thymunox),
produced on the base of synthetic pentapeptid by the firm Cilag AG
International (Switzerland). The main advantage of the IMMUNOFAN is
its ability to stimulate markedly antiviral immunity. The recommended
single dose of IMMUNOFAN is 1-1,5 mcg/kg of the body mass, but that of
Thymopentin (Thymunox) is about 700 mcg/kg.